Alzheimer’s Blood Test Serves as a Crystal Ball

River D'Almeida, Ph.D
2 min readAug 4, 2020

You can’t find your car keys, missed an important Zoom meeting, and draw a blank when it comes to planning what to cook for dinner. Just another weekday or red flags indicating the early signs of Alzheimer’s disease? According to a recent study, the answers could lie in a simple blood test.

Oskar Hansson, Professor of Clinical Memory Research at Lund University, Sweden led an international team of neuroscientists and neurologists who banded together as part of the BioFINDER study in search of improved early detection methods for Alzheimer’s. 50 million people worldwide have Alzheimer’s or related dementia, but of these, experts suggest only 1-in-4 have been diagnosed. There is no accepted clinical procedure for diagnosing or predicting Alzheimer’s, with doctors typically getting confirmation only after a patient’s death. The presence of telltale amyloid plaques and tau tangles (clumps of misfolded proteins in the spaces between nerve cells) are pathologic markers confirming the devastating neurological condition.

The BioFINDER study identified a new biomarker circulating in the blood — phospho-tau217, or p-tau217 — which holds immense promise in predicting future onset, up to 20 years before cognitive symptoms begin.

“While more work is needed to optimize the assay and test it in other people before it becomes…

--

--

River D'Almeida, Ph.D

Follow me for bite-sized stories on the latest discoveries and innovations in biomedical research.